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Reinhard Pechan,t Eva Reiss,* Gunther Rollich,* and
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Carcinogen-induced point mutations resulting in activation of ras oncogenes have been demonstrated
invarious experimental systems such as skin carcinogenesis, mammary, and livercarcinogenesis. In many
cases, the data support the conclusion that these point mutations are critical changes in the initiation of
these tumors. The Syrian hamster embryo (SHE) cell transformation model system has been widely used
to study the multistep process ofchemically induced neoplastic transformation. Recent data suggest that
activation ofthe Ha-ras gene via point mutation is one ofthe crucial events in the transformation ofthese
cells. We have now cloned the c-Ha-ras proto-oncogene from SHE cDNA-libraries, and we have performed
polymerase chain reaction and direct sequencing to analyze tumorcell lines induced by different chemical
carcinogens for the presence ofpoint mutations. No changes were detectable at codons 12, 13, 59, 61, and
117 or adjacent regions in tumor cell lines induced by diethylstilbestrol, asbestos, benzo(a)pyrene, tren-
bolone, or aflatoxin B1. Thus, it is not known whether point mutations in the Ha-ras proto-oncogene are
essential for the acquisition of the neoplastic phenotype of SHE cells. Activation of other oncogenes or
inactivation of tumor suppressor genes may be responsible for the neoplastic progression of these cells.
However, in SHE cells neoplastically transformed by diethylstilbestrol or trenbolone, a significant ele-
vation ofthe c-Ha-ras expression was observed. Enhanced expression ofc-myc was detected in SHE cells
transformed by benzo(a)pyrene or trenbolone.
Introduction
Mechanisms of carcinogen-induced activation of on-
cogenes are being widely studied, and the implications
of the results are highly important for understanding
the genotoxicity of chemicals. The importance of the
results is illustrated by the fact that carcinogen-induced
point mutations resulting in activation of ras oncogenes
have been demonstrated in skin carcinogenesis (1),
mammary (2), and liver carcinogenesis (3). In many
cases, the data indicate that these point mutations are
critical changes in the initiation of tumors. These find-
ings provide strong experimental evidence for relating
the most commonly studied end point with genotoxic
activity of chemicals in carcinogenesis. Furthermore,
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the identification of specific base pair substitutions in
oncogenes allows toxicologiststo evaluate the relevance
ofspecific carcinogen metabolites and carcinogen-DNA
adducts.
The Syrian hamster embryo (SHE) cell transforma-
tion model system has been widely used to study the
multistep process of chemically induced neoplastic
transformation. DNAs from 5 of 12 carcinogen-induced
SHE cell lines were shown to cause transformed foci in
NIH 3T3 cells. The focus cells contained hamster re-
petitive sequences and novel Ha-ras restriction pat-
terns (as revealed by Southern hybridization experi-
ments). Electrophoresis of p21 ras proteins from
transformed foci showed an altered protein with slower
mobility, indicating a possible point mutation in codon
12 (4). These data suggest that activation ofthe Ha-ras
gene via point mutation is one ofthe key events in the
transformation of SHE cells. As we have cloned the
Syrian hamster c-Ha-ras gene, we are now able to ana-
lyze SHE DNA directly for the presence of point mu-
tations in this gene.
Changes in gene expression have been discussed as
a further mode ofactivation ofcellular oncogenes, e.g.,
forc-myc and c-Ha-ras. Generearrangements (5-7) andEBERT ET AL.
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FIGURE 1. SHE c-Ha-ras wild-type sequences around codons 12/13 (A), 59/61 (B), and 116/117 (C).
changes in DNA methylation (8) have been identified
as possible reasons for these alterations. Therefore we
have investigated the transcriptional frequency of c-
myc and c-Ha-ras in various cell lines transformed by
different chemical carcinogens.
Materials and Methods
Normal, nontransformed SHE fibroblasts were iso-
lated from 12-day-old embryos as previously described
(9). After treatment with chemicals, the cells were re-
peatedly subcultured before reaching confluence. In
general, senescence occurred between passages 8 and
15. Immortalized cells escaping senescence were sub-
cultured until passage 70 to 80 and subsequently in-
jected into thymus aplastic mice, giving rise to fibro-
sarcomas at the injection site. The tumors developed
within 4 to 6 weeks. Subsequently, different tumor cell
lines were derived from the obtained tissue.
TocloneaSyrianhamsterc-Ha-rascDNA, twocDNA
libraries were screened with a 460 bp fragment of v-
Ha-ras (BS9) (10). Positive clonesweresequencedusing
direct sequencing of double strand miniprep DNA
(11,12).
c-Ha-ras sequences were amplified by polymerase
chain reaction (PCR) as described (13). Briefly, 1 to 2
,ug genomic DNA was subjected to 35 cycles of ampli-
fication using ampliTaq (Perkin Elmer Cetus). The ap-
propriate sequencing primers were end-labeled with
2P-ATP using T4 polynucleotide kinase, annealed to
PCR-generated DNA, and elongated with cloned T7
DNA polymerase and a ddNTP/dNTP mix. Samples
were analyzed on 8% acrylamide/urea gels. Southern
and Northern blotting and hybridization experiments
were performed according to Maniatis et al. (14).
Results
After screening two Syrian hamster cDNA libraries,
we isolated and sequenced 12 Ha-ras positive clones. A
comparison to known c-Ha-ras coding sequences (15,16)
revealed a homology of 95% to rat and 89% to human.
The deduced amino acid sequence ofthe Syrianhamster
p21 Ha-ras protein is identical to that ofrat and human.
Using the sequence data, we analyzed 14 tumor cell
lines foractivating point mutations inthe c-Ha-ras gene
by means of PCR and direct sequencing (Fig. 1). The
cell lines investigated had been induced with
benzo(a)pyrene (BaP), N-methylnitrosourea (NMU),
diethylstilbestrol (DES), asbestos, or aflatoxin
B1(AFB,). No point mutations were detected in codons
12, 13, 59, 61, 117, or surrounding regions (Table 1).
Northern analysis revealed enhanced expression of c-
Ha-rasincelllinestransformed orimmortalizedbyDES
or trenbolone. Under the influence ofDES, levels of c-
Ha-ras mRNA were elevated only at a late stage, i.e.,
in tumor cells, whereas trenbolone caused an elevated
transcription ofthis gene already in preneoplastic cells
of early passage. In addition, transcriptional levels of
c-myc were enhanced in celllines inducedbytrenbolone
and BaP. Again, trenbolone-treated cells already re-
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Table 1. Results of direct sequencing of DNA from SHE cells
and tumor cell lines generated by various carcinogens.
Codon
Cell line 12 13 59 61 117
SHE cells (wt) GGA GGC GCA CAA AAG
DES Ti wta wt wt wt NDb
DEST2 wt wt wt wt wt
DES T3 wt wt wt wt wt
DES T4 wt wt wt wt wt
DES T5 wt wt wt wt wt
DES T6 wt wt wt wt wt
BaP Ti wt wt wt wt wt
BaP T2 wt wt wt wt NDb
BaqP TPA T wt wt wt wt wt
Trenbolon T wt wt wt wt wt
AFB1T wt wt wt wt wt
NMU T wt wt wt wt wt
IQ T wt wt wt wt wt
Asbestos T wt wt wt wt wt
awt, Wild type.
bND, not determined.
Table 2. mRNA levels of c-Ha-ras and c-myc in chemically
transformed SHE cell lines.
Passage number
Cell line 10/25 60 Tumor
Levels ofc-Ha-ras expression
Trenbolon 6 NDa 6
Diethylstilbestrol 1 1-2 6.5
Diethylstilbestrol treated
with ConA 1-2
Levels of c-myc expression
Trenbolon 6 ND" 6
Diethylstilbestrol 1 1 1
aND, not determined.
vealed this elevation in the preneoplastic state (Table
2).
The degree of DNA methylation is inversely corre-
latedwith geneexpression(17), andinvitromethylation
of a number of genes causes inhibition oftheir expres-
sion after transfer into cells. It is known that Concan-
avalin A (ConA) is able to activate the de novo meth-
ylatingactivityofcytosine-5-methyltransferase without
affecting the maintenance methylation activity of this
enzyme (18). Moreover, ConA inhibits tumor cell
growth in vivo and in vitro (19). ConA (1 ,ug/mL, non-
agglutinating dose) induces growth inhibition after 5
days in a SHE cell line neoplastically transformed by
DES (DES T2), while DNA methylation is increased
simultaneously (Fig. 2). No change in growth and de
novo methylation ofnormal SHE cells was found under
the same conditions. Since it is known that expression
of c-Ha-ras is influenced by its methylation status (8),
we have investigated whether ConA-mediated de novo
methylation reduces c-Ha-ras overexpression in a DES
tumor cell line in which this gene showed a 6-fold over-
expression compared to nornal SHE cells. In fact, we
found a reduction to 1- to 2-fold expression after 48 hr
ConA treatment (Table 2).
4
3.
0 a a
a
a
C)
CJ
U)
2-
1 -
Co A B C
130
z
-120 0
F
I-I 110 2
z a
- 100
- CELL NUMBER
* METHYLATION
FIGURE 2. Growth inhibition and simultaneous DNA methylation
increase of DES-transforned SHE cells 5 days after treatment
withConcanavalinA. Concentrations ofConcanavalinAusedwere
0.1 ,g/mL (A), 0.5 ,g/mL(B), 1.0 ,ug/mL(C). Coindicatescontrol.
Discussion
Theabsenceofpointmutationsinallchemicallytrans-
formed Syrianhamstercelllinesexamined mayindicate
that c-Ha-ras activation via point mutation is not in-
volvedinthetransformation ofthesecells, althoughthis
might have been expected from the kind of primary
DNA interaction of some of the chemicals used (e.g,
NMU, BaP, AFB1). At the present, we cannot exclude
the involvement of other ras genes (Ki-ras, N-ras),
which might also be a target for these chemicals. The
possible existence of small subpopulations carrying c-
Ha-ras mutations also cannot be ruled out. Therefore,
we are currently screening morphologically trans-
formed foci using PCR and direct sequencing to have
accesstotheveryearlystageofchemicalcarcinogenesis
after 10 to 12 cell divisions. In DES- and trenbolone-
transformed tumor cell lines, enhanced expression of
the c-Ha-ras gene may contribute to their malignant
state. In case of DES-induced cells, a correlation of c-
Ha-ras transcription with their proliferation rate was
detected. It is known that enhanced c-Ha-ras expres-
sion of the normal or the mutated gene is sufficient to
induce cell transformation (20).
Furthermore, our results suggest that stimulation of
de novo DNAmethylationreduces oncogene expression
and most likely, as a consequence, tumor cell growth.
Thus our findings provide a possible new approach to
influence the malignantphenotype oftransformed cells.
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